News
1ST Biotherapeutics Joins The Michael J. Fox Foundation’s LITE Program to Advance LRRK2-Based Parkinson’s Disease Research
— Focus on the discovery of next-generation LRRK2 inhibitors to unlock novel biological mechanisms of action and advance new treatment options
1ST Biotherapeutics, Inc. (1STBIO), a clinical-stage biopharmaceutical company focused on advancing therapies for neurodegenerative diseases and cancer, today announced its participation in The Michael J. Fox Foundation for Parkinson’s Research (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE) program. As an industry partner in this initiative, 1STBIO will bring innovative approaches to LRRK2 research and accelerate the development of new therapies for Parkinson’s patients.
Ebenbuild Contributes Cutting-Edge Digital Lung Simulations to Pulmonary Fibrosis Drug Development
— First-ever use of Ebenbuild’s Twinhale technology in idiopathic pulmonary fibrosis lung models
— Trial results published in Nature Communications
Ebenbuild, a company developing personalized, AI-enabled digital twins of lungs to support clinical decisions and digital clinical trials, today announced its contribution to a pioneering study published today in Nature Communications. The article titled Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment(DOI:10.1038/s41467-025-58568-x) highlights the potential of inhaled therapeutics for treating idiopathic pulmonary fibrosis (IPF), a devastating lung disease with limited treatment options. Read more…
New Clinical Data on BellaSeno’s Novel, Resorbable Breast Implants Presented at The Aesthetic MEET 2025
— Presentation by Prof. Anand Deva highlights 87% breast volume retention and low complication rate in one-year patient follow-up
— Successful vascularization and vessel formation in two-year follow-up
— 3D-printed resorbable scaffold to preserve both volume and shape of autologous fat in the medium to long term
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced that Prof. Anand Deva presented new clinical data on BellaSeno’s novel, 3D-printed, resorbable breast scaffolds at The Aesthetic MEET 2025 conference in Austin, TX, USA.
AMYRA Publishes Landmark Review Supporting New Gluten Digestion Approach for Celiac Disease
— Findings highlight underexplored role of intestinal brush border in protein digestion, and its vulnerability to inflammatory damage in celiac disease
— Review discusses potential benefits of supplementing brush border exopeptidase activity in celiac disease patients
AMYRA Biotech AG, a leader in pioneering approaches to digestive health, today announced it published a peer-reviewed literature review in Alimentary Pharmacology & Therapeutics [https://onlinelibrary.wiley.com/doi/10.1111/apt.70014]. The review summarizes current knowledge on gluten-digesting enzyme therapies for celiac disease and underlines the benefits of exploring exopeptidase supplementation as a novel therapeutic paradigm. Read more…